<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Supraventricular arrhythmias during pregnancy</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Supraventricular arrhythmias during pregnancy</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Supraventricular arrhythmias during pregnancy</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Candice Silversides, MD, MS, FRCPC</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Louise Harris, MBChB</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Sing-Chien Yap, MD, PhD</a></dd><dt><span> </span>Section Editors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Hugh Calkins, MD</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">N A Mark Estes, III, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Susan B Yeon, MD, JD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Sep 25, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H11407702"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Arrhythmias are the most common cardiac complication encountered during pregnancy in females with and without structural heart disease [<a href="#rid1">1-3</a>]. In the United States, the incidence of pregnancy-related hospitalizations with arrhythmias has increased between 2000 and 2012 primarily due to increases in the incidence of atrial fibrillation and ventricular tachycardia [<a href="#rid4">4</a>]. </p><p>Arrhythmias may manifest for the first time during pregnancy, and in other cases, pregnancy can trigger exacerbations in those with pre-existing arrhythmias [<a href="#rid1">1,5,6</a>]. Females with established arrhythmias or structural heart disease are at highest risk of developing arrhythmias during pregnancy. In addition, there has been an increase in the number of female patients of childbearing age with congenital heart disease due to surgical advances and improvements in the care of adults with congenital heart disease, and these are at particularly high risk for arrhythmias  (<a class="graphic graphic_figure graphicRef61986" href="/z/d/graphic/61986.html" rel="external">figure 1</a>) [<a href="#rid1">1,2,7-11</a>]. Because of these associations, any pregnant person who presents with an arrhythmia should have a clinical evaluation with a complete history and cardiac examination, an electrocardiogram, and a transthoracic echocardiogram to evaluate for evidence of structural heart disease.</p><p>In general, the approach to the treatment of arrhythmias in pregnancy is similar to that in the nonpregnant patient. However, due to the theoretical or known adverse effects of antiarrhythmic drugs on the fetus, antiarrhythmic drugs are often reserved for the treatment of arrhythmias associated with clinically significant symptoms or hemodynamic compromise [<a href="#rid12">12-14</a>]. Treatment recommendations are hampered by the lack of randomized trials and very little or no data on efficacy or safety of antiarrhythmic drugs during pregnancy. Choice of therapy, for the most part, is based on limited data from animal studies, case reports, and observational studies, as well as clinical experience.</p><p>The prevalence, clinical presentation, and management of supraventricular arrhythmias during pregnancy will be reviewed. Electrocardiographic characteristics of supraventricular arrhythmias, as well as issues relating to conduction disorders, ventricular arrhythmias, and cardiac arrest during pregnancy, are discussed separately. (See  <a class="medical medical_review" href="/z/d/html/2118.html" rel="external">"ECG tutorial: Atrial and atrioventricular nodal (supraventricular) arrhythmias"</a> and  <a class="medical medical_review" href="/z/d/html/15252.html" rel="external">"Maternal conduction disorders and bradycardia during pregnancy"</a> and  <a class="medical medical_review" href="/z/d/html/13601.html" rel="external">"Ventricular arrhythmias during pregnancy"</a>.)</p><p class="headingAnchor" id="H11407709"><span class="h1">MECHANISM OF ARRHYTHMOGENESIS IN PREGNANCY</span><span class="headingEndMark"> — </span>The exact mechanism of increased arrhythmia burden during pregnancy is unclear, but has been attributed to hemodynamic, hormonal, and autonomic changes related to pregnancy.</p><p>The hemodynamic changes of pregnancy have been well studied, and a number of these changes likely contributes to the development of arrhythmias during pregnancy [<a href="#rid15">15-17</a>]. (See  <a class="medical medical_review" href="/z/d/html/443.html" rel="external">"Maternal adaptations to pregnancy: Cardiovascular and hemodynamic changes"</a>.)</p><p>Intravascular volume increases, augmenting the preload on the ventricles and increasing both atrial and ventricular size [<a href="#rid15">15,18-21</a>]. Atrial and ventricular myocardial stretch may contribute to arrhythmogenesis, due to stretch-activated ion channel activity causing membrane depolarization, shortened refractoriness, slowed conduction, and spatial dispersion of refractoriness and conduction [<a href="#rid22">22-25</a>]. There is also an increase in resting heart rate, which has been associated with markers of arrhythmogenesis such as late potentials, premature ventricular contractions, and depressed heart rate variability [<a href="#rid26">26</a>]. </p><p>Few studies have been published on the influence of hormonal and autonomic changes on arrhythmogenesis in pregnancy. Although catecholamine levels do not appear to change during pregnancy, there is an increase in adrenergic responsiveness during pregnancy [<a href="#rid27">27-31</a>]. This increased adrenergic activity during pregnancy may also contribute to enhanced automaticity and triggered activity [<a href="#rid32">32</a>]. </p><p class="headingAnchor" id="H11407716"><span class="h1">SYMPTOM-RHYTHM CORRELATION</span><span class="headingEndMark"> — </span>Palpitations occur frequently during pregnancy and are a common indication for cardiac evaluation during pregnancy. The differential diagnosis of palpitations is extensive and the diagnostic evaluation of pregnant individuals with palpitations does not differ from nonpregnant individuals. (See  <a class="medical medical_review" href="/z/d/html/6835.html" rel="external">"Evaluation of palpitations in adults"</a>.)</p><p>One study compared 110 pregnant females with symptoms suggestive of possible arrhythmia (palpitations: 87 percent; dizziness: 13 percent; syncope/presyncope: 6 percent) with 52 pregnant females evaluated for a functional murmur [<a href="#rid33">33</a>]. Prevalence of supraventricular and ventricular ectopic activity on 24-hour Holter ambulatory monitoring was similar in the symptomatic and control groups. </p><p>Only 10 percent of symptomatic episodes were accompanied by the presence of arrhythmias. A sensation of palpitations during pregnancy, in the absence of concomitant cardiac arrhythmias, may be related to the high output state, including increased heart rate, decreased peripheral resistance, and increased stroke volumes. (See  <a class="medical medical_review" href="/z/d/html/443.html" rel="external">"Maternal adaptations to pregnancy: Cardiovascular and hemodynamic changes"</a>.)</p><p>In another study of 96 patients with symptoms, event loop recorders confirmed benign arrhythmias in the majority of patients. The longer monitoring allowed for better detection of more complex arrhythmias [<a href="#rid34">34</a>]. </p><p class="headingAnchor" id="H11407723"><span class="h1">ATRIAL PREMATURE BEATS</span><span class="headingEndMark"> — </span>Premature atrial complexes (PACs; also referred to a premature atrial beat, premature supraventricular complex, or premature supraventricular beat) are very frequent in pregnant patients and the prevalence is dependent on the duration of observation. (See  <a class="medical medical_review" href="/z/d/html/932.html" rel="external">"Supraventricular premature beats"</a>.)</p><p>In one study of 162 pregnancies in patients with structurally normal hearts evaluated with 24-hour Holter monitoring, the prevalence of PACs was 57 percent and frequent PACs (&gt;100 PACs per 24 hours) occurred in six percent of pregnancies [<a href="#rid33">33</a>]. There was a significant reduction in the frequency of atrial and ventricular ectopic activity in nine patients in whom Holter monitoring was repeated postpartum.</p><p class="headingAnchor" id="H11407730"><span class="h2">Clinical presentation</span><span class="headingEndMark"> — </span>PACs produce few or no symptoms in the majority of pregnant patients, although some people may have symptoms of palpitations. </p><p class="headingAnchor" id="H11407737"><span class="h2">Management</span><span class="headingEndMark"> — </span>No therapy is required for PACs in the asymptomatic woman. Pregnant persons with symptomatic PACs should be reassured of the benign nature of PACs and be advised to discontinue potential precipitant factors such as smoking, coffee intake, alcohol intake, or other stimulants.</p><p>If ectopic activity continues and is associated with intolerable symptoms, treatment with cardioselective beta blockers such as <a class="drug drug_general" data-topicid="9645" href="/z/d/drug information/9645.html" rel="external">metoprolol</a> can be effective. (See <a class="local">'Issues regarding antiarrhythmic drug treatment'</a> below.)</p><p class="headingAnchor" id="H11407744"><span class="h1">PAROXYSMAL SUPRAVENTRICULAR TACHYCARDIA</span><span class="headingEndMark"> — </span>Paroxysmal supraventricular tachycardia (PSVT) describes a tachycardia that is caused, in the vast majority of patients, either by reentry within the atrioventricular (AV) node or by use of an accessory pathway, either manifest or concealed. (See  <a class="medical medical_review" href="/z/d/html/902.html" rel="external">"Atrioventricular nodal reentrant tachycardia"</a>.)</p><p>In pregnant patients with structurally normal hearts, AV nodal reentrant tachycardia (AVNRT) is the most common PSVT, followed by AV reciprocating tachycardia (AVRT) [<a href="#rid5">5</a>]. The prevalence of PSVT has been estimated at 22 to 24 per 100,000 hospital admissions in pregnant patients [<a href="#rid4">4,35</a>]. A population-based cohort study of pregnancies in Taiwan between 2001 and 2012 demonstrated that PSVT in pregnant patients was associated with severe maternal morbidity, cesarean deliveries, low birth weight babies, preterm labor, and obvious fetal abnormalities in comparison with females without PSVT [<a href="#rid36">36</a>]. These data should be interpreted with caution, however, as there are a number of possible explanations for this association: while PSVT in pregnancy may be directly detrimental to the developing fetus, PSVT may also be associated with other maternal factors that impact maternal and fetal health, and patients presenting with PSVT may have had more intensive fetal monitoring as a consequence of their presentation with PSVT, with possible earlier delivery and lower birth weight. </p><p>There are discrepancies between studies as to whether pregnancy increases the risk of first onset of PSVT [<a href="#rid5">5,37</a>]. One study of 38 patients with PSVT and a previous pregnancy found that the initial onset of PSVT occurred during pregnancy in 13 patients (34 percent). The estimated relative risk of first onset of PSVT during pregnancy was 5.1 (95 percent confidence interval 2.8 to 9.2) [<a href="#rid37">37</a>]. In contrast, another study of 173 patients with symptomatic PSVT and a history of pregnancy referred for electrophysiologic testing and radiofrequency catheter ablation, reported that only 4.6 percent had initial onset of PSVT during pregnancy [<a href="#rid5">5</a>]. In that series, pregnancy was not associated with first onset of PSVT. Furthermore, in patients with AVNRT there was a decreased risk of first onset of AVNRT during pregnancy (relative risk 0.11, 95% CI 0.02-0.56).</p><p>The same study found that among patients with a first onset of PSVT before pregnancy, the majority (85 percent) of patients had an exacerbation of PSVT during pregnancy [<a href="#rid5">5</a>]. Exacerbations of PSVT during pregnancy were more symptomatic (assessed by a semiquantitative questionnaire) when compared with arrhythmias during nonpregnant periods.</p><p class="headingAnchor" id="H11407751"><span class="h2">Clinical presentation</span><span class="headingEndMark"> — </span>The presentation of PSVT during pregnancy is the same as in the nonpregnant state and includes symptoms of palpitations that may be associated with presyncope, syncope, dyspnea, and/or chest pain. Patients with PSVT typically describe a regular and rapid tachycardia of abrupt onset, with or without abrupt termination. The clinical and hemodynamic consequences of the arrhythmia depend on many variables including the presence or absence of structural heart disease. For example, in women with Ebstein’s anomaly of the tricuspid valve, symptomatic AVRT episodes can result in serious hemodynamic deterioration [<a href="#rid13">13,38</a>]. PSVT is usually well tolerated in pregnant patients without structural heart disease [<a href="#rid39">39-43</a>].</p><p class="headingAnchor" id="H2955272064"><span class="h2">Management</span><span class="headingEndMark"> — </span>Our management approach is in general agreement with the recommendations for pregnant patients made by professional society guidelines for the management of patients with supraventricular tachycardia [<a href="#rid11">11,13,44</a>]. </p><p class="headingAnchor" id="H11407758"><span class="h3">Management of acute episodes</span><span class="headingEndMark"> — </span>If hemodynamic compromise is evident, direct-current cardioversion should be performed [<a href="#rid11">11,44</a>]. (See  <a class="medical medical_review" href="/z/d/html/983.html" rel="external">"Cardioversion for specific arrhythmias"</a> and  <a class="medical medical_review" href="/z/d/html/975.html" rel="external">"Basic principles and technique of external electrical cardioversion and defibrillation"</a> and  <a class="medical medical_review" href="/z/d/html/983.html" rel="external">"Cardioversion for specific arrhythmias", section on 'Cardioversion during pregnancy'</a>.)</p><p>When the patient is hemodynamically stable, acute episodes of PSVT may be terminated by transiently blocking AV nodal conduction [<a href="#rid11">11</a>]. If vagal maneuvers (eg, Valsalva maneuver or carotid sinus massage) fail, intravenous <a class="drug drug_general" data-topicid="9359" href="/z/d/drug information/9359.html" rel="external">adenosine</a> (6 to 18 mg) is an appropriate choice in pregnancy, terminating approximately 90 percent of PSVT [<a href="#rid45">45</a>]. Case reports have demonstrated the effectiveness of adenosine in pregnant patients, although in most of the reports adenosine was administrated in the second and third trimester [<a href="#rid46">46</a>]. (See  <a class="medical medical_review" href="/z/d/html/902.html" rel="external">"Atrioventricular nodal reentrant tachycardia", section on 'Initial management'</a>.)</p><p><a class="drug drug_general" data-topicid="9359" href="/z/d/drug information/9359.html" rel="external">Adenosine</a> has a very short half-life (&lt;10 seconds), reducing the placental exposure to adenosine. Despite reduced adenosine deaminase activity during pregnancy (25 percent) [<a href="#rid47">47</a>], the adenosine dose required for PSVT termination during pregnancy is not reduced, possibly due to the increased volume of distribution [<a href="#rid48">48</a>]. (See <a class="local">'Issues regarding antiarrhythmic drug treatment'</a> below.)</p><p>Recommended second-line drugs are intravenous beta-1 selective blockers [<a href="#rid11">11,44,46</a>]. The experience with intravenous <a class="drug drug_general" data-topicid="10043" href="/z/d/drug information/10043.html" rel="external">verapamil</a> is limited [<a href="#rid49">49</a>], and the longer half-life (5.3 hours) of verapamil can cause significant hypotension, especially when given as a rapid intravenous bolus injection [<a href="#rid48">48</a>]. (See <a class="local">'Issues regarding antiarrhythmic drug treatment'</a> below.)</p><p class="headingAnchor" id="H11407765"><span class="h3">Prophylactic pharmacologic therapy</span><span class="headingEndMark"> — </span>Prevention of PSVT in patients without WPW syndrome can be accomplished with a number of AV nodal blocking agents (ie, beta-1 selective blockers [except <a class="drug drug_general" data-topicid="8940" href="/z/d/drug information/8940.html" rel="external">atenolol</a>] or <a class="drug drug_general" data-topicid="10043" href="/z/d/drug information/10043.html" rel="external">verapamil</a>, in order of preference) [<a href="#rid11">11,13,48,50,51</a>]. In pregnant patients without structural heart disease who have PSVT not controlled with AV nodal blocking agents, <a class="drug drug_general" data-topicid="8449" href="/z/d/drug information/8449.html" rel="external">flecainide</a>, <a class="drug drug_general" data-topicid="9821" href="/z/d/drug information/9821.html" rel="external">propafenone</a>, or <a class="drug drug_general" data-topicid="9941" href="/z/d/drug information/9941.html" rel="external">sotalol</a> can be considered for the prevention of PSVT [<a href="#rid11">11,13,50</a>]. In pregnant patients with WPW syndrome and without ischemic or structural heart disease, flecainide or propafenone are options for the prevention of PSVT [<a href="#rid11">11,13</a>]. (See <a class="local">'Issues regarding antiarrhythmic drug treatment'</a> below and  <a class="medical medical_review" href="/z/d/html/902.html" rel="external">"Atrioventricular nodal reentrant tachycardia", section on 'Preventive therapy'</a>.)</p><p>Experience with <a class="drug drug_general" data-topicid="9360" href="/z/d/drug information/9360.html" rel="external">digoxin</a> is extensive and it is considered safe during pregnancy [<a href="#rid52">52</a>]. However, the efficacy of digoxin for prophylaxis has not been demonstrated. One small, randomized, cross-over study of 11 nonpregnant patients showed that there was similar efficacy between digoxin, <a class="drug drug_general" data-topicid="9829" href="/z/d/drug information/9829.html" rel="external">propranolol</a>, and <a class="drug drug_general" data-topicid="10043" href="/z/d/drug information/10043.html" rel="external">verapamil</a> with respect to the frequency or duration of PSVT [<a href="#rid53">53</a>]. Propranolol and <a class="drug drug_general" data-topicid="9645" href="/z/d/drug information/9645.html" rel="external">metoprolol</a> are often used, but the potential fetal risks of beta blockers need to be discussed with the mother, in particular the risk of intra-uterine growth restriction [<a href="#rid51">51</a>] (see <a class="local">'Issues regarding antiarrhythmic drug treatment'</a> below). <a class="drug drug_general" data-topicid="8940" href="/z/d/drug information/8940.html" rel="external">Atenolol</a> should not be used for treatment of arrhythmias if alternative medications are available. </p><p>Because pregnancy may exacerbate PSVT, radiofrequency catheter ablation is recommended in symptomatic patients with recurrent PSVT who plan to become pregnant [<a href="#rid11">11</a>]. In patients with malignant, drug-resistant arrhythmias, radiofrequency catheter ablation during pregnancy may be an option in selected cases [<a href="#rid11">11,13,54</a>]. (See <a class="local">'Radiofrequency catheter ablation'</a> below and  <a class="medical medical_review" href="/z/d/html/902.html" rel="external">"Atrioventricular nodal reentrant tachycardia"</a>.) </p><p>In general, anticoagulation therapy is not indicated for SVT such as AVNRT, AVRT over a bypass tract, or ectopic atrial tachycardia.</p><p class="headingAnchor" id="H11407772"><span class="h1">FOCAL ATRIAL TACHYCARDIA</span><span class="headingEndMark"> — </span>Focal atrial tachycardia is relatively rare during pregnancy. (See  <a class="medical medical_review" href="/z/d/html/900.html" rel="external">"Focal atrial tachycardia"</a>.)</p><p>Although this arrhythmia is often associated with structural heart disease in nonpregnant patients, most reports of atrial tachycardia during pregnancy have been reported in patients without apparent structural heart disease [<a href="#rid42">42,43</a>].</p><p class="headingAnchor" id="H11407779"><span class="h2">Clinical presentation</span><span class="headingEndMark"> — </span>As in the nonpregnant state, this arrhythmia is often persistent and can be refractory to treatment, including direct current (DC) cardioversion [<a href="#rid42">42,43</a>]. Because many atrial tachycardias are caused by enhanced automaticity, vagal maneuvers or the use of antiarrhythmic agents that decrease atrioventricular nodal conduction (eg, <a class="drug drug_general" data-topicid="9359" href="/z/d/drug information/9359.html" rel="external">adenosine</a>, <a class="drug drug_general" data-topicid="9360" href="/z/d/drug information/9360.html" rel="external">digoxin</a>, beta blockers, calcium channel blockers), will usually not terminate the arrhythmia [<a href="#rid42">42,43</a>]. </p><p>In most reported cases, the arrhythmia subsides and terminates shortly after delivery, suggesting that pregnancy may contribute to the initiation and maintenance of this tachyarrhythmia [<a href="#rid42">42,43</a>]. </p><p class="headingAnchor" id="H11407786"><span class="h2">Diagnosis and management</span><span class="headingEndMark"> — </span>The differentiation between atrial tachycardia and other supraventricular tachyarrhythmias may be difficult. (See  <a class="medical medical_review" href="/z/d/html/943.html" rel="external">"Narrow QRS complex tachycardias: Clinical manifestations, diagnosis, and evaluation"</a>.)</p><p>The administration of <a class="drug drug_general" data-topicid="9359" href="/z/d/drug information/9359.html" rel="external">adenosine</a> may be useful as a therapeutic and diagnostic tool. Because atrial tachycardia is difficult to treat and is generally well tolerated by the mother and the fetus, urgent DC cardioversion or administration of multiple intravenous drugs is not recommended when pregnant patients are hemodynamically stable. </p><p>The goal of therapy should be to achieve adequate rate control. The risk of not treating an incessant atrial tachycardia is the development of a tachycardia-induced cardiomyopathy [<a href="#rid55">55</a>]. (See  <a class="medical medical_review" href="/z/d/html/1062.html" rel="external">"Arrhythmia-induced cardiomyopathy"</a>.)</p><p>Rate control can be achieved with beta blockers, <a class="drug drug_general" data-topicid="9360" href="/z/d/drug information/9360.html" rel="external">digoxin</a>, or <a class="drug drug_general" data-topicid="10043" href="/z/d/drug information/10043.html" rel="external">verapamil</a> [<a href="#rid11">11,42-44,50</a>], with reservation of <a class="drug drug_general" data-topicid="9941" href="/z/d/drug information/9941.html" rel="external">sotalol</a>, <a class="drug drug_general" data-topicid="8449" href="/z/d/drug information/8449.html" rel="external">flecainide</a>, or <a class="drug drug_general" data-topicid="9821" href="/z/d/drug information/9821.html" rel="external">propafenone</a>  (<a class="graphic graphic_table graphicRef50716" href="/z/d/graphic/50716.html" rel="external">table 1</a>) [<a href="#rid43">43,48,56</a>]. Decisions regarding the use of other antiarrhythmic drugs or consideration of ablation should be made with the assistance of an electrophysiologist. </p><p>For patients with hemodynamically significant atrial tachycardia with a rapid ventricular response who do not respond to medical therapy and do not have a reversible precipitating cause, DC cardioversion may be required. However, as noted above, atrial tachycardias may be particularly resistant to cardioversion. (See  <a class="medical medical_review" href="/z/d/html/983.html" rel="external">"Cardioversion for specific arrhythmias", section on 'Cardioversion during pregnancy'</a> and <a class="local">'Electrical cardioversion'</a> below.)</p><p>In some pregnant patients with incessant atrial tachycardia, radiofrequency catheter ablation may need to be considered [<a href="#rid11">11,13,54,57</a>]. (See <a class="local">'Radiofrequency catheter ablation'</a> below and  <a class="medical medical_review" href="/z/d/html/900.html" rel="external">"Focal atrial tachycardia"</a>.)</p><p class="headingAnchor" id="H11407793"><span class="h1">ATRIAL FIBRILLATION AND FLUTTER</span><span class="headingEndMark"> — </span>The management of atrial fibrillation is often similar in pregnancy compared with the non-pregnant state. Unique considerations include:</p><p class="bulletIndent1"><span class="glyph">●</span>Choice of specific pharmacotherapy to maximize safety and minimize adverse effects during pregnancy and lactation.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Hemodynamic changes across pregnancy and labor and delivery, particularly in pregnant patients with structural heart disease.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Recognition of pregnancy as a hypercoagulable, prothrombotic state.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Early and frequent labor and delivery planning throughout pregnancy. This includes shared decision-making between the patient and multidisciplinary care team. </p><p></p><p class="headingAnchor" id="H1128582401"><span class="h2">Epidemiology and risk factors</span><span class="headingEndMark"> — </span>Atrial fibrillation and flutter during pregnancy are relatively uncommon. In an Agency for Healthcare Research Quality database of &gt;1200 hospitals across the United States, the prevalence of atrial fibrillation was 27 per 100,000 pregnancy-related hospital admissions, and atrial flutter was 4 per 100,000 [<a href="#rid4">4</a>]. This study found that atrial fibrillation rates nearly doubled from 2000 to 2012 (18 to 35 per 100,000 hospital admissions). Advancing maternal age and higher burden of AF risk factors (hypertension, diabetes mellitus, obesity, and congenital heart disease) over this time period likely explain increased atrial fibrillation rates.</p><p>Although atrial fibrillation and flutter can occur in pregnant patients with structurally normal hearts [<a href="#rid58">58,59</a>], they are more common in pregnant patients with structural heart disease, such as rheumatic heart disease, valvular heart disease, hypertrophic cardiomyopathy [<a href="#rid60">60</a>], peripartum cardiomyopathy, and congenital heart disease [<a href="#rid6">6,61-63</a>]. (See  <a class="medical medical_review" href="/z/d/html/1004.html" rel="external">"Epidemiology, risk factors, and prevention of atrial fibrillation"</a> and  <a class="medical medical_review" href="/z/d/html/1048.html" rel="external">"Overview of atrial flutter"</a>.) </p><p>Metabolic disturbances such as hyperthyroidism, electrolyte imbalances, and alcohol use can also contribute to the development of atrial fibrillation during pregnancy.</p><p class="headingAnchor" id="H11407800"><span class="h2">Clinical presentation</span><span class="headingEndMark"> — </span>The clinical presentation and hemodynamic consequences of atrial fibrillation and flutter depend on many variables, including the underlying heart condition and the associated ventricular response rate. In addition to hemodynamic consequences, pregnant patients with atrial fibrillation are at increased risk of systemic embolism both from hemostatic changes seen in normal pregnancy [<a href="#rid64">64</a>] and from atrial fibrillation. (See  <a class="medical medical_review" href="/z/d/html/1031.html" rel="external">"Atrial fibrillation in adults: Use of oral anticoagulants"</a>.)</p><p>Common presenting symptoms of atrial fibrillation in pregnancy are palpitations, feeling of rapid heart beating, heart fluttering, lightheadedness, syncope, or dyspnea. </p><p>Atrial fibrillation is less well tolerated in persons with preexisting structural heart disease. Symptoms may be further exacerbated by pregnancy-related physiologic changes, such as increased blood volume, increased heart rate, shunting of blood to the uteroplacental system, and anemia. Symptoms include concomitant pulmonary edema, dyspnea at rest and on exertion, dizziness, and syncope due to rise in left atrial pressure and lower stroke volume. </p><p>Structural heart conditions that predispose to atrial fibrillation and flutter, and are seen in pregnant patients, include mitral stenosis, congenital heart disease, and other conditions causing heart failure [<a href="#rid65">65</a>]. These conditions are described in detail separately:</p><p class="bulletIndent1"><span class="glyph">●</span>Mitral stenosis. (See  <a class="medical medical_review" href="/z/d/html/8173.html" rel="external">"Rheumatic mitral stenosis: Clinical manifestations and diagnosis"</a>.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Congenital heart disease [<a href="#rid62">62</a>] or preexisting heart failure. (See  <a class="medical medical_review" href="/z/d/html/1422.html" rel="external">"Pregnancy in women with congenital heart disease: General principles"</a>.) </p><p></p><p>Another scenario that can present for the first time in pregnancy is conduction down an antegrade accessory pathway that produces rapid atrial fibrillation. (See  <a class="medical medical_review" href="/z/d/html/962.html" rel="external">"Wolff-Parkinson-White syndrome: Anatomy, epidemiology, clinical manifestations, and diagnosis", section on 'Atrial fibrillation'</a>.)</p><p>A study of pregnancy-related hospitalizations (from 2000 to 2012) demonstrated that AF is the most frequent arrhythmia in pregnancy and the frequency has been increasing over time, and that maternal and/or fetal complications are more common in women with arrhythmias in general [<a href="#rid4">4</a>]. </p><p class="headingAnchor" id="H11407807"><span class="h2">Diagnostic testing</span><span class="headingEndMark"> — </span>As with the nonpregnant patient, atrial fibrillation and flutter can be associated with structural heart disease in females of childbearing age; thus, all pregnant patients presenting with these arrhythmias should have a thorough clinical investigation. (See  <a class="medical medical_review" href="/z/d/html/1022.html" rel="external">"Atrial fibrillation: Overview and management of new-onset atrial fibrillation"</a>.)</p><p>The evaluation includes:</p><p class="bulletIndent1"><span class="glyph">●</span>History and physical examination.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Electrocardiogram.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Transthoracic echocardiogram.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Continuous cardiac rhythm monitoring to assess arrhythmia burden and average heart rate.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Search for any obvious provoking factor (eg, hyperthyroidism, electrolyte imbalances, pulmonary embolism, alcohol abuse) with treatment of the precipitant as necessary.</p><p></p><p class="headingAnchor" id="H1339507101"><span class="h2">Management</span><span class="headingEndMark"> — </span>Management, as with the nonpregnant patient, includes treatment of acute episodes, prevention of systemic embolization, and deciding on a rate versus rhythm control strategy. In the pregnant patient, it is important to discuss the labor and delivery plan as early as possible in pregnancy using a multidisciplinary team-based, shared decision-making approach. </p><p>We agree with the recommendations for pregnant patients made in the 2020 European Society of Cardiology (ESC) guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery [<a href="#rid14">14</a>] and the 2018 ESC guidelines for the management of cardiovascular diseases during pregnancy [<a href="#rid13">13,14</a>]. </p><p class="headingAnchor" id="H11407814"><span class="h3">Management of acute episodes</span><span class="headingEndMark"> — </span>Much of the management of acute atrial fibrillation is similar in pregnant and nonpregnant persons. </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Hemodynamic instability</strong> – Episodes of atrial fibrillation and flutter that cause hemodynamic instability require emergent direct current (DC) cardioversion [<a href="#rid13">13,48</a>]. Atrial fibrillation with rapid ventricular rates in pregnant patients with preexcitation is also best treated with DC cardioversion. (See <a class="local">'Electrical cardioversion'</a> below.)</p><p></p><p class="bulletIndent1">Some patients may require concomitant initiation of anticoagulati<em>o</em>n. </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>No hemodynamic instability</strong> – For pregnant patients who are hemodynamically stable, either electrical or pharmacological cardioversion can be attempted. The choice of approach is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/1025.html" rel="external">"Atrial fibrillation: Cardioversion", section on 'Electrical versus pharmacologic cardioversion'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prevention of embolization</strong> – For patients in whom immediate cardioversion is not needed, it is important to recognize that if an episode of AF lasts more than 48 hours, or is of unknown duration, a transesophageal echocardiogram should be performed to rule out left atrial appendage thrombus, or systemic anticoagulation should be maintained for three weeks prior to electrical or pharmacologic cardioversion. Systemic anticoagulation is needed for at least four weeks following cardioversion [<a href="#rid14">14</a>]. This is discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/906.html" rel="external">"Prevention of embolization prior to and after restoration of sinus rhythm in atrial fibrillation", section on 'AF duration uncertain or 48 or more hours'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Pharmacological cardioversion</strong> – In pregnant patients, <a class="drug drug_general" data-topicid="8449" href="/z/d/drug information/8449.html" rel="external">flecainide</a>  (<a class="graphic graphic_table graphicRef50716" href="/z/d/graphic/50716.html" rel="external">table 1</a>) is used to achieve cardioversion [<a href="#rid13">13,14</a>]. In the pregnant patient, <a class="drug drug_general" data-topicid="8548" href="/z/d/drug information/8548.html" rel="external">ibutilide</a> is avoided after the first trimester, as there is little experience with its use [<a href="#rid14">14</a>]. <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">Amiodarone</a> is also avoided due to potential fetotoxicity [<a href="#rid66">66,67</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Obstetric care</strong> – For the pregnant patient with atrial fibrillation or flutter, decisions about hospitalization for an acute atrial fibrillation episode and whether to perform fetal monitoring should be coordinated with the obstetrics care providers. </p><p></p><p class="headingAnchor" id="H889561568"><span class="h3">Rhythm control versus rate control</span><span class="headingEndMark"> — </span>During pregnancy, we prefer a rhythm control strategy for newly diagnosed atrial fibrillation and for patients who remain symptomatic with a rate-control strategy. This approach differs from nonpregnant patients, where more consideration is given to pursuing rate control, particularly in patients without structural heart disease. This is discussed separately. (See  <a class="medical medical_review" href="/z/d/html/1045.html" rel="external">"Management of atrial fibrillation: Rhythm control versus rate control"</a>.) </p><p class="bulletIndent1"><span class="glyph">●</span><strong>Rhythm control</strong> – <a class="drug drug_general" data-topicid="8449" href="/z/d/drug information/8449.html" rel="external">Flecainide</a> in the absence of structural heart disease or <a class="drug drug_general" data-topicid="9941" href="/z/d/drug information/9941.html" rel="external">sotalol</a> in the absence of left ventricular systolic dysfunction should be considered to prevent atrial fibrillation if AV nodal-blocking drugs fail [<a href="#rid13">13,14,48</a>]. <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">Amiodarone</a> is not typically used in pregnancy due to its potential fetal teratogenic effects. (See  <a class="medical medical_review" href="/z/d/html/1035.html" rel="external">"Antiarrhythmic drugs to maintain sinus rhythm in patients with atrial fibrillation: Recommendations"</a>.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Rate control</strong> – If rhythm control cannot be achieved or is unlikely to be successful, then ventricular rate control can be instituted. In pregnant patients, beta-selective blockers are recommended for rate control [<a href="#rid13">13,14,48</a>]. If beta blockers fail, <a class="drug drug_general" data-topicid="9360" href="/z/d/drug information/9360.html" rel="external">digoxin</a> or <a class="drug drug_general" data-topicid="10043" href="/z/d/drug information/10043.html" rel="external">verapamil</a> should be considered. These are used alone or in combination to control the ventricular response rate [<a href="#rid68">68</a>]. <a class="drug drug_general" data-topicid="8595" href="/z/d/drug information/8595.html" rel="external">Amiodarone</a> is not typically used in pregnancy due to its potential fetal teratogenic effects. (See  <a class="medical medical_review" href="/z/d/html/938.html" rel="external">"Control of ventricular rate in patients with atrial fibrillation who do not have heart failure: Pharmacologic therapy"</a>.)</p><p></p><p class="headingAnchor" id="H11407828"><span class="h3">Anticoagulation</span><span class="headingEndMark"> — </span>Pregnancy is associated with a prothrombotic state and increased thromboembolic risk. However, risk stratification for stroke in atrial fibrillation has not been extensively studied in regard to pregnant patients; only one small retrospective study demonstrated that the CHA<sub>2</sub>DS<sub>2</sub>-VASc score may underestimate the risk of stroke in pregnant patients [<a href="#rid69">69</a>]. </p><p>Anticoagulation is recommended for stroke prevention in pregnant patients with atrial fibrillation or flutter and additional thromboembolic risk factors as in the nonpregnant patient [<a href="#rid48">48</a>]. (See  <a class="medical medical_review" href="/z/d/html/128998.html" rel="external">"Atrial fibrillation in adults: Selection of candidates for anticoagulation", section on 'CHA2DS2-VASc score'</a> and  <a class="medical medical_review" href="/z/d/html/1022.html" rel="external">"Atrial fibrillation: Overview and management of new-onset atrial fibrillation", section on 'Classification and terminology'</a>.)</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Preferred anticoagulant</strong> – The preferred anticoagulant for most patients is low molecular weight heparin. Heparin can be used throughout all stages of pregnancy but should be discontinued prior to delivery. (See  <a class="medical medical_review" href="/z/d/html/1342.html" rel="external">"Use of anticoagulants during pregnancy and postpartum"</a> and  <a class="medical medical_review" href="/z/d/html/1342.html" rel="external">"Use of anticoagulants during pregnancy and postpartum", section on 'LMW heparin'</a> and  <a class="medical medical_review" href="/z/d/html/1342.html" rel="external">"Use of anticoagulants during pregnancy and postpartum", section on 'Timing for starting LMW heparin'</a>.)</p><p></p><p class="bulletIndent1">Management of antithrombotic therapy for pregnant patients with prosthetic heart valves is discussed in detail separately. (See  <a class="medical medical_review" href="/z/d/html/8126.html" rel="external">"Management of antithrombotic therapy for a prosthetic heart valve during pregnancy"</a>.)</p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="10050" href="/z/d/drug information/10050.html" rel="external">Warfarin</a> is often not used in pregnancy because of the risk of embryopathy and fetopathy. Similarly, novel oral anticoagulants are not recommended during pregnancy because of the lack of safety data and the potential fetal toxicity at high doses [<a href="#rid13">13,14</a>]. (See  <a class="medical medical_review" href="/z/d/html/1342.html" rel="external">"Use of anticoagulants during pregnancy and postpartum"</a>.) </p><p></p><p class="headingAnchor" id="H3322520113"><span class="h3">Labor and delivery plan</span><span class="headingEndMark"> — </span>If a patient is on anticoagulation, it should be held at the time of labor and delivery. </p><p>It is reasonable to obtain a 12-lead electrocardiogram upon arrival to labor and delivery. If the patient is in atrial fibrillation, they have had a high burden of atrial fibrillation, they have had problems with rate control, or there is structural heart disease, the use of telemetry is reasonable in order to monitor heart rate and rhythm. </p><p>Close coordination between the patient and multidisciplinary cardio-obstetrics team (including cardiology, high-risk obstetrics, maternal fetal medicine, neonatology, social work, and anesthesia providers) to develop the labor and delivery plan for patients with atrial fibrillation and flutter is important [<a href="#rid70">70,71</a>]. (See  <a class="medical medical_review" href="/z/d/html/8148.html" rel="external">"Acquired heart disease and pregnancy", section on 'Management of labor and delivery'</a>.)</p><p class="headingAnchor" id="H11407891"><span class="h1">ISSUES REGARDING ANTIARRHYTHMIC DRUG TREATMENT</span><span class="headingEndMark"> — </span>The rate of placental passage of any drug is dependent on lipid solubility, molecular weight, protein binding, ionization, fetal and placental blood flow, and pH of maternal and fetal fluids. Nonionized, nonprotein bound, lipid soluble drugs with molecular weight below 600 Daltons freely cross the placenta [<a href="#rid72">72</a>], while high molecular weight drugs are not transported in significant amounts. Almost all antiarrhythmic drugs cross the placenta. Fetal tissues begin to differentiate during the period of organogenesis (gestational weeks 5 to 10) and are most susceptible to the effects of teratogens at that time. The major concern with antiarrhythmic drugs taken during the second and third trimesters are potential adverse effects on fetal growth and development, drug-related side effects in the neonate, risk of proarrhythmia, and possible effects on uterine contractility. </p><p class="headingAnchor" id="H11407898"><span class="h2">Safety during pregnancy</span><span class="headingEndMark"> — </span>Safety profiles of antiarrhythmic drugs are drawn from case reports, case series, registry data, and case control and cohort studies of pregnant patients treated with these drugs, alone or with other agents, and for a variety of indications, including hypertension, maternal or fetal arrhythmias, and a wide spectrum of underlying medical disorders, which could confound findings. There are no data from large well-designed randomized trials on which to base a recommendation for use of one drug over another. Data regarding both comparative efficacy in improving maternal outcome and fetal safety are inadequate for almost all antiarrhythmic drugs.</p><p>Information related to the toxicity and teratogenicity of medications in pregnant patients must be interpreted in light of the background risk of adverse pregnancy outcomes in any pregnant woman. Major birth defects are defined as events of medical, surgical, or cosmetic significance. It is estimated that the prevalence of major birth defects is 2 to 4 percent among live born infants, and in utero growth restriction occurs in 3 to 10 percent of pregnancies, depending on the definition used. Intrauterine growth restriction can be related to in utero drug exposure, the mother's disease, other drug therapy, or a combination of these and other factors (eg, intrinsic fetal or placental factors).</p><p>Since 1975, the United States Food and Drug Administration (FDA) has assigned pregnancy risk factors to all drugs available in the United States. Information on the use of specific drugs in pregnancy, including the FDA risk category and pregnancy implications, is available in the UpToDate drug database. Specific information on the fetal and neonatal risks of maternal drug ingestion during pregnancy and lactation are also available from the following website: <a class="external" href="/external-redirect?target_url=http%3A%2F%2Fwww.perinatology.com%2Fexposures%2Fdruglist.htm&amp;token=jc3SKr4sVgyEWB4Td3cb57yGHj2Qi19M4OPzpmAAijOuo4jqvraRneIps79GZ%2F8NQr2IEfOFnfnIDmQ2klTUJQ%3D%3D&amp;TOPIC_ID=13600" target="_blank">www.perinatology.com/exposures/druglist.htm</a>.</p><p>The following table provides a brief synopsis of pregnancy and breastfeeding implications for the drugs discussed in this topic  (<a class="graphic graphic_table graphicRef50716" href="/z/d/graphic/50716.html" rel="external">table 1</a>). </p><p class="headingAnchor" id="H11407912"><span class="h2">Pharmacokinetic changes during pregnancy</span><span class="headingEndMark"> — </span>Physiological changes during pregnancy may alter the absorption, excretion and effective plasma concentration of all antiarrhythmic drugs. Increased intravascular volumes during pregnancy may require an increase in loading dose. Gastrointestinal absorption of drugs may be altered by changes in gastric secretion and intestinal motility. Increase in renal blood flow and progesterone-induced increase of hepatic metabolism may augment drug clearance [<a href="#rid73">73</a>]. Finally, decreased serum protein concentrations may reduce protein binding, decreasing the total drug concentration and leading to greater fluctuation in unbound drug concentration. These pharmacokinetic changes may explain why pregnant patients previously stable on antiarrhythmic therapy have breakthrough arrhythmias. Because of intra-individual variability in the above-mentioned factors, drug dose should be optimized on an individual basis with monitoring of clinical response.</p><p class="headingAnchor" id="H11407919"><span class="h2">Breast feeding</span><span class="headingEndMark"> — </span>In general, drugs that are most likely to be transferred from maternal plasma to milk have the following characteristics: nonionized, nonprotein bound, low molecular weight, high lipid solubility, and high pH. In addition to drug transfer, drug clearance in the setting of a neonate's immature renal and hepatic function also determines whether a drug and/or its metabolites reach therapeutic or toxic levels in the infant.</p><p>The LactMed database, produced by the National Library of Medicine, provides monographs on many prescription and over-the-counter medications. The <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fbooks%2FNBK501922%2F%3Freport%3Dclassic&amp;token=wEsKVFvqlKzpT%2BqOtddW%2Fy3%2BLj0shalBW%2BL1ZyL4trxbRM9n9k9jxarxPZM5TS5htB9tQgQ%2BhkEZ6u8L6V76cKfsHR1IKbAngeDe8Jfsj0k%3D&amp;TOPIC_ID=13600" target="_blank">database</a> is available free of charge. The UpToDate drug database also provides information on lactation and breastfeeding implications for all drugs in the database.</p><p>The following table provides a brief synopsis of pregnancy and breastfeeding implications for drugs discussed in this topic  (<a class="graphic graphic_table graphicRef50716" href="/z/d/graphic/50716.html" rel="external">table 1</a>). </p><p class="headingAnchor" id="H11407926"><span class="h1">ISSUES REGARDING NON-PHARMACOLOGIC TREATMENT</span></p><p class="headingAnchor" id="H11407933"><span class="h2">Electrical cardioversion</span><span class="headingEndMark"> — </span>Emergent or elective electrical cardioversion can be performed at all stages of pregnancy [<a href="#rid13">13,48,74</a>], and should be used for any sustained arrhythmia with hemodynamic compromise and can be considered for drug-refractory arrhythmias. In the third trimester, some physicians prefer to perform electrical cardioversion under general anesthesia and intubation, considering the more difficult airway and increased risk of gastric aspiration during pregnancy. Electrical cardioversion does not result in compromise of blood flow to the fetus [<a href="#rid74">74</a>]. While there is a theoretical risk of inducing an arrhythmia in the fetus, this risk is very small due to the high fibrillation threshold and small amount of energy reaching the fetus. Nonetheless, postprocedure continuous electronic fetal heart rate monitoring is recommended because of reported cases of emergency cesarean delivery due to fetal arrhythmias [<a href="#rid75">75</a>]. </p><p>In one multicenter study, 27 pregnant females had 29 electrical cardioversions for supraventricular arrythmias (atrial fibrillation [44 percent], atrial flutter [30 percent], SVT [19 percent], atrial tachycardia [7 percent]) [<a href="#rid76">76</a>]. There were no maternal or fetal deaths. Median gestation at cardioversion was 28 weeks, and median gestation at delivery was 35 weeks. Postprocedure fetal monitoring was undertaken following cardioversion in nearly half the patients and in 7 percent, urgent delivery was required postcardioversion due to fetal bradycardia.</p><p class="headingAnchor" id="H11407940"><span class="h2">Radiofrequency catheter ablation</span><span class="headingEndMark"> — </span>In nonpregnant patients, more definitive treatment of atrial fibrillation, atrial flutter, and other arrhythmias can be accomplished with catheter ablation. (See  <a class="medical medical_review" href="/z/d/html/1007.html" rel="external">"Overview of catheter ablation of cardiac arrhythmias", section on 'Introduction'</a>.)</p><p>Catheter ablation prior to pregnancy is recommended in patients with symptomatic arrhythmias [<a href="#rid11">11</a>]. Ablation of atrial flutter and other arrhythmias is generally avoided during pregnancy given the need for fluoroscopy. For those experiencing new onset of arrhythmias suitable for radiofrequency ablation, or worsening of existing arrhythmias during pregnancy, ablation is generally delayed until after delivery.</p><p>Experience with radiofrequency catheter ablation during pregnancy has been limited to cases of supraventricular tachycardia [<a href="#rid54">54,57,77-84</a>]. These procedures are generally not performed during pregnancy, mainly due to concerns of ionizing radiation exposure to the fetus. However, in rare cases, patients with severe and drug-resistant arrhythmias during pregnancy may be considered for an ablation procedure [<a href="#rid11">11,13,48</a>]. The risk of radiation exposure for the fetus during a typical ablation is small (&lt;1 mGy at all periods of gestation), and is mainly attributable to scatter from the thorax of the mother [<a href="#rid85">85</a>]. (See  <a class="medical medical_review" href="/z/d/html/4791.html" rel="external">"Diagnostic imaging in pregnant and lactating patients"</a>.) </p><p>Cases of successful ablation of atrial tachycardia using intracardiac echocardiography and electro-anatomic mapping without fluoroscopy have been reported [<a href="#rid86">86,87</a>].</p><p class="headingAnchor" id="H587892907"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/112091.html" rel="external">"Society guideline links: Atrial fibrillation"</a> and  <a class="medical medical_society_guidelines" href="/z/d/html/112260.html" rel="external">"Society guideline links: Arrhythmias in adults"</a>.)</p><p class="headingAnchor" id="H889561628"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Symptoms </strong>– Palpitations occur frequently during pregnancy and are a common indication for cardiac evaluation during pregnancy. (See <a class="local">'Symptom-rhythm correlation'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Evaluation for structural heart disease </strong>–<strong> </strong>Since cardiac arrhythmias are frequently associated with structural heart disease, any woman who presents with an arrhythmia during pregnancy should undergo clinical evaluation for structural heart disease. including an electrocardiogram and a transthoracic echocardiogram. (See <a class="local">'Diagnostic testing'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Paroxysmal supraventricular tachycardia </strong>– In pregnant patients with structurally normal hearts, paroxysmal supraventricular tachycardia (PSVT), including atrioventricular (AV)-nodal reentrant tachycardia and AV-reciprocating tachycardia, is the most common arrhythmia. Management of PSVT is performed with AV-nodal blocking agents. If hemodynamic compromise is evident, direct current (DC) cardioversion should be performed. (See <a class="local">'Paroxysmal supraventricular tachycardia'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Atrial fibrillation and flutter</strong> – These arrhythmias occur less frequently than PSVT and are more common in patients with structural heart disease. (See <a class="local">'Atrial fibrillation and flutter'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Hemodynamically unstable pregnant patients require urgent cardioversion. (See <a class="local">'Electrical cardioversion'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>We suggest a rhythm control over a rate control strategy in pregnancy (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). In pregnant patients, we use <a class="drug drug_general" data-topicid="8449" href="/z/d/drug information/8449.html" rel="external">flecainide</a>, <a class="drug drug_general" data-topicid="9821" href="/z/d/drug information/9821.html" rel="external">propafenone</a>, or <a class="drug drug_general" data-topicid="9941" href="/z/d/drug information/9941.html" rel="external">sotalol</a>  (<a class="graphic graphic_table graphicRef50716" href="/z/d/graphic/50716.html" rel="external">table 1</a>). (See <a class="local">'Rhythm control versus rate control'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>If rhythm control cannot be achieved or is unlikely to be successful, then ventricular rate control can be instituted. Rate-control agents in pregnancy include beta-selective blockers, <a class="drug drug_general" data-topicid="10043" href="/z/d/drug information/10043.html" rel="external">verapamil</a>, and <a class="drug drug_general" data-topicid="9360" href="/z/d/drug information/9360.html" rel="external">digoxin</a>  (<a class="graphic graphic_table graphicRef50716" href="/z/d/graphic/50716.html" rel="external">table 1</a>), either alone or in combination.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Although pregnancy is a prothrombotic state, given the lack of extensive data on risk stratification during pregnancy, similar recommendations for stroke risk assessment should be used as those in nonpregnant patients. (See  <a class="medical medical_review" href="/z/d/html/128998.html" rel="external">"Atrial fibrillation in adults: Selection of candidates for anticoagulation"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>The preferred anticoagulant for most pregnant patients is low molecular weight heparin. Heparin can be used throughout all stages of pregnancy but should be discontinued prior to delivery. (See <a class="local">'Anticoagulation'</a> above.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>The labor and delivery plan</strong> – Pregnant patients with arrhythmia should develop an early birth/labor plan with their multidisciplinary team including cardiology, OB-GYN, and anesthesia. A 12-lead electrocardiogram upon arrival to labor and delivery and telemetry may be indicated. (See <a class="local">'Labor and delivery plan'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Information on the use of specific antiarrhythmic drugs in pregnancy is available in the UpToDate drug database. (See <a class="local">'Issues regarding antiarrhythmic drug treatment'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Siu SC, Sermer M, Colman JM, et al. Prospective multicenter study of pregnancy outcomes in women with heart disease. Circulation 2001; 104:515.</a></li><li><a class="nounderline abstract_t">Drenthen W, Pieper PG, Roos-Hesselink JW, et al. Outcome of pregnancy in women with congenital heart disease: a literature review. J Am Coll Cardiol 2007; 49:2303.</a></li><li><a class="nounderline abstract_t">Drenthen W, Boersma E, Balci A, et al. Predictors of pregnancy complications in women with congenital heart disease. Eur Heart J 2010; 31:2124.</a></li><li><a class="nounderline abstract_t">Vaidya VR, Arora S, Patel N, et al. Burden of Arrhythmia in Pregnancy. Circulation 2017; 135:619.</a></li><li><a class="nounderline abstract_t">Lee SH, Chen SA, Wu TJ, et al. Effects of pregnancy on first onset and symptoms of paroxysmal supraventricular tachycardia. Am J Cardiol 1995; 76:675.</a></li><li><a class="nounderline abstract_t">Silversides CK, Harris L, Haberer K, et al. Recurrence rates of arrhythmias during pregnancy in women with previous tachyarrhythmia and impact on fetal and neonatal outcomes. Am J Cardiol 2006; 97:1206.</a></li><li><a class="nounderline abstract_t">Siu SC, Sermer M, Harrison DA, et al. Risk and predictors for pregnancy-related complications in women with heart disease. Circulation 1997; 96:2789.</a></li><li><a class="nounderline abstract_t">Drenthen W, Pieper PG, Ploeg M, et al. Risk of complications during pregnancy after Senning or Mustard (atrial) repair of complete transposition of the great arteries. Eur Heart J 2005; 26:2588.</a></li><li><a class="nounderline abstract_t">Drenthen W, Pieper PG, van der Tuuk K, et al. Cardiac complications relating to pregnancy and recurrence of disease in the offspring of women with atrioventricular septal defects. Eur Heart J 2005; 26:2581.</a></li><li><a class="nounderline abstract_t">Drenthen W, Pieper PG, Roos-Hesselink JW, et al. Pregnancy and delivery in women after Fontan palliation. Heart 2006; 92:1290.</a></li><li><a class="nounderline abstract_t">Brugada J, Katritsis DG, Arbelo E, et al. 2019 ESC Guidelines for the management of patients with supraventricular tachycardiaThe Task Force for the management of patients with supraventricular tachycardia of the European Society of Cardiology (ESC). Eur Heart J 2020; 41:655.</a></li><li><a class="nounderline abstract_t">Joglar JA, Page RL. Treatment of cardiac arrhythmias during pregnancy: safety considerations. Drug Saf 1999; 20:85.</a></li><li><a class="nounderline abstract_t">Regitz-Zagrosek V, Roos-Hesselink JW, Bauersachs J, et al. 2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy. Eur Heart J 2018; 39:3165.</a></li><li><a class="nounderline abstract_t">Hindricks G, Potpara T, Dagres N, et al. 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J 2021; 42:373.</a></li><li class="breakAll">Silversides CK, Colman JM. Physiological changes in pregnancy. In: Heart disease in pregnancy, 2nd ed, Oakley C, Warnes CA (Eds), Blackwell Publishing, Malden 2007. p.6.</li><li class="breakAll">Elkayam U, Gleicher N. Hemodynamics and cardiac function during normal pregnancy and puerperium. In: Cardiac problems in pregnancy, 3rd ed, Elkayam U, Gleicher N (Eds), Wiley-Liss, New York 1998. p.3.</li><li><a class="nounderline abstract_t">Sanghavi M, Rutherford JD. Cardiovascular physiology of pregnancy. Circulation 2014; 130:1003.</a></li><li><a class="nounderline abstract_t">Katz R, Karliner JS, Resnik R. Effects of a natural volume overload state (pregnancy) on left ventricular performance in normal human subjects. Circulation 1978; 58:434.</a></li><li><a class="nounderline abstract_t">Rubler S, Damani PM, Pinto ER. Cardiac size and performance during pregnancy estimated with echocardiography. Am J Cardiol 1977; 40:534.</a></li><li><a class="nounderline abstract_t">Liebson PR, Mann LI, Evans MI, et al. Cardiac performance during pregnancy: serial evaluation using external systolic time intervals. Am J Obstet Gynecol 1975; 122:1.</a></li><li><a class="nounderline abstract_t">Campos O. Doppler Echocardiography During Pregnancy: Physiological and Abnormal Findings. Echocardiography 1996; 13:135.</a></li><li><a class="nounderline abstract_t">Franz MR, Cima R, Wang D, et al. Electrophysiological effects of myocardial stretch and mechanical determinants of stretch-activated arrhythmias. Circulation 1992; 86:968.</a></li><li><a class="nounderline abstract_t">Wang Y, Joyner RW, Wagner MB, et al. Stretch-activated channel activation promotes early afterdepolarizations in rat ventricular myocytes under oxidative stress. Am J Physiol Heart Circ Physiol 2009; 296:H1227.</a></li><li><a class="nounderline abstract_t">Ninio DM, Saint DA. The role of stretch-activated channels in atrial fibrillation and the impact of intracellular acidosis. Prog Biophys Mol Biol 2008; 97:401.</a></li><li><a class="nounderline abstract_t">Kamkin A, Kiseleva I, Isenberg G. Stretch-activated currents in ventricular myocytes: amplitude and arrhythmogenic effects increase with hypertrophy. Cardiovasc Res 2000; 48:409.</a></li><li><a class="nounderline abstract_t">Soliman EZ, Elsalam MA, Li Y. The relationship between high resting heart rate and ventricular arrhythmogenesis in patients referred to ambulatory 24 h electrocardiographic recording. Europace 2010; 12:261.</a></li><li><a class="nounderline abstract_t">Zuspan FP. Catecholamines. Their role in pregnancy and the development of pregnancy-induced hypertension. J Reprod Med 1979; 23:143.</a></li><li><a class="nounderline abstract_t">Natrajan PG, McGarrigle HH, Lawrence DM, Lachelin GC. Plasma noradrenaline and adrenaline levels in normal pregnancy and in pregnancy-induced hypertension. Br J Obstet Gynaecol 1982; 89:1041.</a></li><li><a class="nounderline abstract_t">Whittaker PG, Gerrard J, Lind T. Catecholamine responses to changes in posture during human pregnancy. Br J Obstet Gynaecol 1985; 92:586.</a></li><li><a class="nounderline abstract_t">Barron WM, Mujais SK, Zinaman M, et al. Plasma catecholamine responses to physiologic stimuli in normal human pregnancy. Am J Obstet Gynecol 1986; 154:80.</a></li><li><a class="nounderline abstract_t">Ramsay MM, Broughton Pipkin F, Rubin PC. Pressor, heart rate and plasma catecholamine responses to noradrenaline in pregnant and nonpregnant women. Br J Obstet Gynaecol 1993; 100:170.</a></li><li><a class="nounderline abstract_t">Priori SG, Mantica M, Schwartz PJ. Delayed afterdepolarizations elicited in vivo by left stellate ganglion stimulation. Circulation 1988; 78:178.</a></li><li><a class="nounderline abstract_t">Shotan A, Ostrzega E, Mehra A, et al. Incidence of arrhythmias in normal pregnancy and relation to palpitations, dizziness, and syncope. Am J Cardiol 1997; 79:1061.</a></li><li><a class="nounderline abstract_t">Cruz MO, Hibbard JU, Alexander T, Briller J. Ambulatory arrhythmia monitoring in pregnant patients with palpitations. Am J Perinatol 2013; 30:53.</a></li><li><a class="nounderline abstract_t">Li JM, Nguyen C, Joglar JA, et al. Frequency and outcome of arrhythmias complicating admission during pregnancy: experience from a high-volume and ethnically-diverse obstetric service. Clin Cardiol 2008; 31:538.</a></li><li><a class="nounderline abstract_t">Chang SH, Kuo CF, Chou IJ, et al. Outcomes Associated With Paroxysmal Supraventricular Tachycardia During Pregnancy. Circulation 2017; 135:616.</a></li><li><a class="nounderline abstract_t">Tawam M, Levine J, Mendelson M, et al. Effect of pregnancy on paroxysmal supraventricular tachycardia. Am J Cardiol 1993; 72:838.</a></li><li><a class="nounderline abstract_t">Smith WM, Gallagher JJ, Kerr CR, et al. The electrophysiologic basis and management of symptomatic recurrent tachycardia in patients with Ebstein's anomaly of the tricuspid valve. Am J Cardiol 1982; 49:1223.</a></li><li><a class="nounderline abstract_t">Gleicher N, Meller J, Sandler RZ, Sullum S. Wolff-Parkinson-White syndrome in pregnancy. Obstet Gynecol 1981; 58:748.</a></li><li><a class="nounderline abstract_t">Widerhorn J, Widerhorn AL, Rahimtoola SH, Elkayam U. WPW syndrome during pregnancy: increased incidence of supraventricular arrhythmias. Am Heart J 1992; 123:796.</a></li><li><a class="nounderline abstract_t">Kounis NG, Zavras GM, Papadaki PJ, et al. Pregnancy-induced increase of supraventricular arrhythmias in Wolff-Parkinson-White syndrome. Clin Cardiol 1995; 18:137.</a></li><li><a class="nounderline abstract_t">Murphy JJ, Hutchon DJ. Incessant atrial tachycardia accelerated by pregnancy. Br Heart J 1992; 68:342.</a></li><li><a class="nounderline abstract_t">Treakle K, Kostic B, Hulkower S. Supraventricular tachycardia resistant to treatment in a pregnant woman. J Fam Pract 1992; 35:581.</a></li><li><a class="nounderline abstract_t">Page RL, Joglar JA, Caldwell MA, et al. 2015 ACC/AHA/HRS Guideline for the Management of Adult Patients With Supraventricular Tachycardia: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol 2016; 67:e27.</a></li><li><a class="nounderline abstract_t">Elkayam U, Goodwin TM. Adenosine therapy for supraventricular tachycardia during pregnancy. Am J Cardiol 1995; 75:521.</a></li><li><a class="nounderline abstract_t">Ghosh N, Luk A, Derzko C, et al. The acute treatment of maternal supraventricular tachycardias during pregnancy: a review of the literature. J Obstet Gynaecol Can 2011; 33:17.</a></li><li><a class="nounderline abstract_t">Jaqueti J, Martinez-Hernández D, Hernández-Garcia R, et al. Adenosine deaminase in pregnancy serum. Clin Chem 1990; 36:2144.</a></li><li><a class="nounderline abstract_t">Joglar JA, Kapa S, Saarel EV, et al. 2023 HRS expert consensus statement on the management of arrhythmias during pregnancy. Heart Rhythm 2023; 20:e175.</a></li><li><a class="nounderline abstract_t">Byerly WG, Hartmann A, Foster DE, Tannenbaum AK. Verapamil in the treatment of maternal paroxysmal supraventricular tachycardia. Ann Emerg Med 1991; 20:552.</a></li><li><a class="nounderline abstract_t">Halpern DG, Weinberg CR, Pinnelas R, et al. Use of Medication for Cardiovascular Disease During Pregnancy: JACC State-of-the-Art Review. J Am Coll Cardiol 2019; 73:457.</a></li><li><a class="nounderline abstract_t">Bateman BT, Heide-Jørgensen U, Einarsdóttir K, et al. β-Blocker Use in Pregnancy and the Risk for Congenital Malformations: An International Cohort Study. Ann Intern Med 2018; 169:665.</a></li><li class="breakAll">Briggs GC, Freeman RK, Yaffe SJ. Drugs in Pregnancy and Lactation, 8th ed, Lippincott Williams &amp; Wilkins, Philadelphia 2008.</li><li><a class="nounderline abstract_t">Winniford MD, Fulton KL, Hillis LD. Long-term therapy of paroxysmal supraventricular tachycardia: a randomized, double-blind comparison of digoxin, propranolol and verapamil. Am J Cardiol 1984; 54:1138.</a></li><li><a class="nounderline abstract_t">Szumowski L, Szufladowicz E, Orczykowski M, et al. Ablation of severe drug-resistant tachyarrhythmia during pregnancy. J Cardiovasc Electrophysiol 2010; 21:877.</a></li><li><a class="nounderline abstract_t">Cruz FE, Cheriex EC, Smeets JL, et al. Reversibility of tachycardia-induced cardiomyopathy after cure of incessant supraventricular tachycardia. J Am Coll Cardiol 1990; 16:739.</a></li><li><a class="nounderline abstract_t">Haines DE, DiMarco JP. Sustained intraatrial reentrant tachycardia: clinical, electrocardiographic and electrophysiologic characteristics and long-term follow-up. J Am Coll Cardiol 1990; 15:1345.</a></li><li><a class="nounderline abstract_t">Pagad SV, Barmade AB, Toal SC, et al. 'Rescue' radiofrequency ablation for atrial tachycardia presenting as cardiomyopathy in pregnancy. Indian Heart J 2004; 56:245.</a></li><li><a class="nounderline abstract_t">Gowda RM, Punukollu G, Khan IA, et al. Lone atrial fibrillation during pregnancy. Int J Cardiol 2003; 88:123.</a></li><li><a class="nounderline abstract_t">Kuczkowski KM. New onset transient lone atrial fibrillation in a healthy parturient: déjà vu. Int J Cardiol 2004; 97:339.</a></li><li><a class="nounderline abstract_t">Autore C, Conte MR, Piccininno M, et al. Risk associated with pregnancy in hypertrophic cardiomyopathy. J Am Coll Cardiol 2002; 40:1864.</a></li><li><a class="nounderline abstract_t">Walsh EP, Cecchin F. Arrhythmias in adult patients with congenital heart disease. Circulation 2007; 115:534.</a></li><li><a class="nounderline abstract_t">Tateno S, Niwa K, Nakazawa M, et al. Arrhythmia and conduction disturbances in patients with congenital heart disease during pregnancy: multicenter study. Circ J 2003; 67:992.</a></li><li><a class="nounderline abstract_t">Balci A, Drenthen W, Mulder BJ, et al. Pregnancy in women with corrected tetralogy of Fallot: occurrence and predictors of adverse events. Am Heart J 2011; 161:307.</a></li><li><a class="nounderline abstract_t">O'Riordan MN, Higgins JR. Haemostasis in normal and abnormal pregnancy. Best Pract Res Clin Obstet Gynaecol 2003; 17:385.</a></li><li><a class="nounderline abstract_t">Salam AM, Ertekin E, van Hagen IM, et al. Atrial Fibrillation or Flutter During Pregnancy in Patients With Structural Heart Disease: Data From the ROPAC (Registry on Pregnancy and Cardiac Disease). JACC Clin Electrophysiol 2015; 1:284.</a></li><li><a class="nounderline abstract_t">Kockova R, Kocka V, Kiernan T, Fahy GJ. Ibutilide-induced cardioversion of atrial fibrillation during pregnancy. J Cardiovasc Electrophysiol 2007; 18:545.</a></li><li><a class="nounderline abstract_t">Burkart TA, Kron J, Miles WM, et al. Successful termination of atrial flutter by ibutilide during pregnancy. Pacing Clin Electrophysiol 2007; 30:283.</a></li><li><a class="nounderline abstract_t">Tan HL, Lie KI. Treatment of tachyarrhythmias during pregnancy and lactation. Eur Heart J 2001; 22:458.</a></li><li><a class="nounderline abstract_t">Giehm-Reese M, Kronborg MB, Lukac P, et al. Recurrent atrial flutter ablation and incidence of atrial fibrillation ablation after first-time ablation for typical atrial flutter: A nation-wide Danish cohort study. Int J Cardiol 2020; 298:44.</a></li><li><a class="nounderline abstract_t">Davis MB, Walsh MN. Cardio-Obstetrics. Circ Cardiovasc Qual Outcomes 2019; 12:e005417.</a></li><li><a class="nounderline abstract_t">Sharma G, Zakaria S, Michos ED, et al. Improving Cardiovascular Workforce Competencies in Cardio-Obstetrics: Current Challenges and Future Directions. J Am Heart Assoc 2020; 9:e015569.</a></li><li><a class="nounderline abstract_t">Syme MR, Paxton JW, Keelan JA. Drug transfer and metabolism by the human placenta. Clin Pharmacokinet 2004; 43:487.</a></li><li><a class="nounderline abstract_t">Dunlop W. Serial changes in renal haemodynamics during normal human pregnancy. Br J Obstet Gynaecol 1981; 88:1.</a></li><li><a class="nounderline abstract_t">Wang YC, Chen CH, Su HY, Yu MH. The impact of maternal cardioversion on fetal haemodynamics. Eur J Obstet Gynecol Reprod Biol 2006; 126:268.</a></li><li><a class="nounderline abstract_t">Barnes EJ, Eben F, Patterson D. Direct current cardioversion during pregnancy should be performed with facilities available for fetal monitoring and emergency caesarean section. BJOG 2002; 109:1406.</a></li><li><a class="nounderline abstract_t">Cauldwell M, Adamson D, Bhatia K, et al. Direct current cardioversion in pregnancy: a multicentre study. BJOG 2023; 130:1269.</a></li><li><a class="nounderline abstract_t">Bongiorni MG, Di Cori A, Soldati E, et al. Radiofrequency catheter ablation of atrioventricular nodal reciprocating tachycardia using intracardiac echocardiography in pregnancy. Europace 2008; 10:1018.</a></li><li><a class="nounderline abstract_t">Risius T, Mortensen K, Meinertz T, Willems S. Cluster of multiple atrial tachycardias limited to pregnancy after radiofrequency ablation following senning operation. Int J Cardiol 2008; 123:e48.</a></li><li><a class="nounderline abstract_t">Kanjwal Y, Kosinski D, Kanj M, et al. Successful radiofrequency catheter ablation of left lateral accessory pathway using transseptal approach during pregnancy. J Interv Card Electrophysiol 2005; 13:239.</a></li><li><a class="nounderline abstract_t">Bombelli F, Lagona F, Salvati A, et al. Radiofrequency catheter ablation in drug refractory maternal supraventricular tachycardias in advanced pregnancy. Obstet Gynecol 2003; 102:1171.</a></li><li><a class="nounderline abstract_t">Domínguez A, Iturralde P, Hermosillo AG, et al. Successful radiofrequency ablation of an accessory pathway during pregnancy. Pacing Clin Electrophysiol 1999; 22:131.</a></li><li><a class="nounderline abstract_t">Berruezo A, Díez GR, Berne P, et al. Low exposure radiation with conventional guided radiofrequency catheter ablation in pregnant women. Pacing Clin Electrophysiol 2007; 30:1299.</a></li><li><a class="nounderline abstract_t">Driver K, Chisholm CA, Darby AE, et al. Catheter Ablation of Arrhythmia During Pregnancy. J Cardiovasc Electrophysiol 2015; 26:698.</a></li><li><a class="nounderline abstract_t">Chen G, Sun G, Xu R, et al. Zero-fluoroscopy catheter ablation of severe drug-resistant arrhythmia guided by Ensite NavX system during pregnancy: Two case reports and literature review. Medicine (Baltimore) 2016; 95:e4487.</a></li><li><a class="nounderline abstract_t">Damilakis J, Theocharopoulos N, Perisinakis K, et al. Conceptus radiation dose and risk from cardiac catheter ablation procedures. Circulation 2001; 104:893.</a></li><li><a class="nounderline abstract_t">Ferguson JD, Helms A, Mangrum JM, DiMarco JP. Ablation of incessant left atrial tachycardia without fluoroscopy in a pregnant woman. J Cardiovasc Electrophysiol 2011; 22:346.</a></li><li><a class="nounderline abstract_t">Szumowski L, Szufladowicz E, Orczykowski M, et al. Ablation of severe drug-resistant tachyarrhythmia during pregnancy. J Cardiovasc Electrophysiol 2010; 21:877.</a></li></ol></div><div id="topicVersionRevision">Topic 13600 Version 34.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11479246" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Prospective multicenter study of pregnancy outcomes in women with heart disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17572244" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Outcome of pregnancy in women with congenital heart disease: a literature review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20584777" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Predictors of pregnancy complications in women with congenital heart disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28154000" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Burden of Arrhythmia in Pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7572623" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Effects of pregnancy on first onset and symptoms of paroxysmal supraventricular tachycardia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16616027" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Recurrence rates of arrhythmias during pregnancy in women with previous tachyarrhythmia and impact on fetal and neonatal outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9386139" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Risk and predictors for pregnancy-related complications in women with heart disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16126718" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Risk of complications during pregnancy after Senning or Mustard (atrial) repair of complete transposition of the great arteries.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16107486" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Cardiac complications relating to pregnancy and recurrence of disease in the offspring of women with atrioventricular septal defects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16449503" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Pregnancy and delivery in women after Fontan palliation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31504425" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : 2019 ESC Guidelines for the management of patients with supraventricular tachycardiaThe Task Force for the management of patients with supraventricular tachycardia of the European Society of Cardiology (ESC).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9935279" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Treatment of cardiac arrhythmias during pregnancy: safety considerations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30165544" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : 2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32860505" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32860505" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32860505" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25223771" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Cardiovascular physiology of pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/679433" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Effects of a natural volume overload state (pregnancy) on left ventricular performance in normal human subjects.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/910718" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Cardiac size and performance during pregnancy estimated with echocardiography.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1130438" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Cardiac performance during pregnancy: serial evaluation using external systolic time intervals.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11442917" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Doppler Echocardiography During Pregnancy: Physiological and Abnormal Findings.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1381296" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Electrophysiological effects of myocardial stretch and mechanical determinants of stretch-activated arrhythmias.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19286952" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Stretch-activated channel activation promotes early afterdepolarizations in rat ventricular myocytes under oxidative stress.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18367236" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : The role of stretch-activated channels in atrial fibrillation and the impact of intracellular acidosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11090836" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Stretch-activated currents in ventricular myocytes: amplitude and arrhythmogenic effects increase with hypertrophy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19887457" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : The relationship between high resting heart rate and ventricular arrhythmogenesis in patients referred to ambulatory 24 h electrocardiographic recording.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/385865" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Catecholamines. Their role in pregnancy and the development of pregnancy-induced hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7171514" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Plasma noradrenaline and adrenaline levels in normal pregnancy and in pregnancy-induced hypertension.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/4005199" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Catecholamine responses to changes in posture during human pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3511708" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Plasma catecholamine responses to physiologic stimuli in normal human pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8476811" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Pressor, heart rate and plasma catecholamine responses to noradrenaline in pregnant and nonpregnant women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3383403" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Delayed afterdepolarizations elicited in vivo by left stellate ganglion stimulation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9114764" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Incidence of arrhythmias in normal pregnancy and relation to palpitations, dizziness, and syncope.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22814871" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Ambulatory arrhythmia monitoring in pregnant patients with palpitations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19006111" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Frequency and outcome of arrhythmias complicating admission during pregnancy: experience from a high-volume and ethnically-diverse obstetric service.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28153999" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Outcomes Associated With Paroxysmal Supraventricular Tachycardia During Pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8213524" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Effect of pregnancy on paroxysmal supraventricular tachycardia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7064845" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : The electrophysiologic basis and management of symptomatic recurrent tachycardia in patients with Ebstein's anomaly of the tricuspid valve.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7312244" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Wolff-Parkinson-White syndrome in pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1539536" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : WPW syndrome during pregnancy: increased incidence of supraventricular arrhythmias.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7743683" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Pregnancy-induced increase of supraventricular arrhythmias in Wolff-Parkinson-White syndrome.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1389773" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Incessant atrial tachycardia accelerated by pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1431774" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Supraventricular tachycardia resistant to treatment in a pregnant woman.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26409259" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : 2015 ACC/AHA/HRS Guideline for the Management of Adult Patients With Supraventricular Tachycardia: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7864004" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Adenosine therapy for supraventricular tachycardia during pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21272431" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : The acute treatment of maternal supraventricular tachycardias during pregnancy: a review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2253371" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Adenosine deaminase in pregnancy serum.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37211147" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : 2023 HRS expert consensus statement on the management of arrhythmias during pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2024796" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Verapamil in the treatment of maternal paroxysmal supraventricular tachycardia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30704579" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Use of Medication for Cardiovascular Disease During Pregnancy: JACC State-of-the-Art Review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30326014" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : β-Blocker Use in Pregnancy and the Risk for Congenital Malformations: An International Cohort Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30326014" id="rid51" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>52 : β-Blocker Use in Pregnancy and the Risk for Congenital Malformations: An International Cohort Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/6388299" id="rid52" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>53 : Long-term therapy of paroxysmal supraventricular tachycardia: a randomized, double-blind comparison of digoxin, propranolol and verapamil.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20158563" id="rid53" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>54 : Ablation of severe drug-resistant tachyarrhythmia during pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2387945" id="rid54" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>55 : Reversibility of tachycardia-induced cardiomyopathy after cure of incessant supraventricular tachycardia.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2329238" id="rid55" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>56 : Sustained intraatrial reentrant tachycardia: clinical, electrocardiographic and electrophysiologic characteristics and long-term follow-up.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15584571" id="rid56" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>57 : 'Rescue' radiofrequency ablation for atrial tachycardia presenting as cardiomyopathy in pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12660001" id="rid57" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>58 : Lone atrial fibrillation during pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15458713" id="rid58" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>59 : New onset transient lone atrial fibrillation in a healthy parturient: déjàvu.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12446072" id="rid59" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>60 : Risk associated with pregnancy in hypertrophic cardiomyopathy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17261672" id="rid60" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>61 : Arrhythmias in adult patients with congenital heart disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14639012" id="rid61" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>62 : Arrhythmia and conduction disturbances in patients with congenital heart disease during pregnancy: multicenter study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21315213" id="rid62" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>63 : Pregnancy in women with corrected tetralogy of Fallot: occurrence and predictors of adverse events.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12787533" id="rid63" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>64 : Haemostasis in normal and abnormal pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29759316" id="rid64" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>65 : Atrial Fibrillation or Flutter During Pregnancy in Patients With Structural Heart Disease: Data From the ROPAC (Registry on Pregnancy and Cardiac Disease).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17286570" id="rid65" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>66 : Ibutilide-induced cardioversion of atrial fibrillation during pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17338730" id="rid66" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>67 : Successful termination of atrial flutter by ibutilide during pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11237540" id="rid67" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>68 : Treatment of tachyarrhythmias during pregnancy and lactation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31521436" id="rid68" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>69 : Recurrent atrial flutter ablation and incidence of atrial fibrillation ablation after first-time ablation for typical atrial flutter: A nation-wide Danish cohort study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30773028" id="rid69" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>70 : Cardio-Obstetrics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32482113" id="rid70" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>71 : Improving Cardiovascular Workforce Competencies in Cardio-Obstetrics: Current Challenges and Future Directions.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15170365" id="rid71" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>72 : Drug transfer and metabolism by the human placenta.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7459285" id="rid72" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>73 : Serial changes in renal haemodynamics during normal human pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16377063" id="rid73" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>74 : The impact of maternal cardioversion on fetal haemodynamics.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12504980" id="rid74" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>75 : Direct current cardioversion during pregnancy should be performed with facilities available for fetal monitoring and emergency caesarean section.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37039253" id="rid75" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>76 : Direct current cardioversion in pregnancy: a multicentre study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18460548" id="rid76" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>77 : Radiofrequency catheter ablation of atrioventricular nodal reciprocating tachycardia using intracardiac echocardiography in pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17349700" id="rid77" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>78 : Cluster of multiple atrial tachycardias limited to pregnancy after radiofrequency ablation following senning operation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16177852" id="rid78" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>79 : Successful radiofrequency catheter ablation of left lateral accessory pathway using transseptal approach during pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14607046" id="rid79" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>80 : Radiofrequency catheter ablation in drug refractory maternal supraventricular tachycardias in advanced pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9990613" id="rid80" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>81 : Successful radiofrequency ablation of an accessory pathway during pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17897139" id="rid81" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>82 : Low exposure radiation with conventional guided radiofrequency catheter ablation in pregnant women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25828853" id="rid82" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>83 : Catheter Ablation of Arrhythmia During Pregnancy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27512864" id="rid83" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>84 : Zero-fluoroscopy catheter ablation of severe drug-resistant arrhythmia guided by Ensite NavX system during pregnancy: Two case reports and literature review.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11514375" id="rid84" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>85 : Conceptus radiation dose and risk from cardiac catheter ablation procedures.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20662991" id="rid85" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>86 : Ablation of incessant left atrial tachycardia without fluoroscopy in a pregnant woman.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20158563" id="rid86" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>87 : Ablation of severe drug-resistant tachyarrhythmia during pregnancy.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
